Additionally, a previous study revealed that ZBTB7A has the potential to bind the promoters and enhancers of NF-κB, and inflammation signaling was an important mediator in the development of NAFLD. Here, ZBTB7A is linked to metabolic dysfunction-associated steatotic liver disease.